News >

NICE Recommends Approval for Ribociclib, Palbociclib for HR+/ HER2- Advanced Breast Cancer

Jason Harris
Published: Thursday, Dec 21, 2017

Carole Longson, PhD

Carole Longson, PhD
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued guidance supporting approval for ribociclib (Kisqali) and palbociclib (Ibrance) for patients with hormone receptor-positive/HER2¬-negative locally advanced or secondary breast cancer.

Both CDK4/6 inhibitors are indicated for use with an aromatase inhibitor (AI). If approved for routine National Health Service (NHS) use, about 8000 newly diagnosed patients in the United Kingdom would be eligible for treatment with the CDK4/6 inhibitors. Ribociclib is produced by Novartis and palbociclib is a Pfizer product.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication